Accura Medical is developing a point-of-care blood test system designed for the physician's office, with the goal of letting patients with cognitive concerns have biomarker testing where they are already seen Accura Medical 正在開發可以直接在診間使用的血液生物標記檢測系統，目標是讓有認知疑慮的患者不必等檢體送出、再等報告回來，在同一次看診裡就完成檢測
Since 2025, the U.S. FDA has cleared blood tests that aid in assessing Alzheimer's-related amyloid pathology, including for use in primary care. Every test cleared to date is a laboratory test: the sample leaves the office, and the result returns after the patient has left. That last step is the one we work on. 自 2025 年起，美國 FDA 已陸續許可數項用於輔助評估阿茲海默症相關類澱粉蛋白病理的血液檢測，其中包括可用於基層醫療的檢測。目前已獲許可的都是實驗室檢測：檢體送出診所，報告回來時患者已經離開。我們做的，就是把這最後一段補起來。
Alzcheck™, our investigational system in development, is designed to measure phosphorylated tau (pTau), an Alzheimer's-related blood biomarker, in the physician's office — with the goal of starting the next conversation within the same visit. 我們研發中的試驗用系統 Alzcheck™，設計用於在醫師診所內檢測血液中的磷酸化 tau 蛋白（pTau），這是一項與阿茲海默症相關的生物標記。目標是讓後續的討論，在同一次看診中就能開始。
A point-of-care result should meet the same standard of clinical evidence as a laboratory result. 定點照護的檢測結果，應達到與實驗室檢測結果相同的臨床證據標準。
A test for primary care has to fit the pace and setting of primary care. 為基層醫療設計的檢測，必須配合基層診所的看診節奏與環境。
Laboratory testing remains essential. Point-of-care testing can extend it to the moment clinician and patient are in the same room. 實驗室檢測仍不可或缺；定點照護檢測則可將其延伸到醫師與患者同在診間的那一刻。
“Every patient with cognitive concerns should be able to access biomarker testing — right in their doctor's office” 「每一位有認知疑慮的患者，都應該能接受生物標記檢測——就在自己醫師的診間」
Clinicians, researchers, partners, and investors — we'd welcome the conversation 醫療專業人員、研究者、合作夥伴與投資人——我們期待與您對話
info@accura.com.tw2F-6, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei, Taiwan 115022115022 台北市南港區忠孝東路七段508號2樓之6